Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster
Eli Lilly agreed in July to pay up to 3.8 billion dollars for AtaiBeckley. The lead asset is an intranasal compound for treatment-resistant depression. Lilly’s own announcement leads on a specific number, and it is not an efficacy number. The average in-clinic visit ran about two hours.
Room design and staffing ratios are decisions clinics make years before a drug is approved. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The pattern | The largest psychedelic deal ever done bought the shortest compound, not the strongest data |
| The benchmark | Spravato already requires a two hour minimum monitoring window, and clinics run it profitably |
| The spread | Candidate session times now range from about 15 minutes to 12 hours |
| Why it matters | Session length sets staffing ratios, room count and patients treated per day |
| The risk | A buildout designed for eight hour sessions may be sized for a product that never arrives |
| Still unknown | Whether payers will reimburse a two hour session and an eight hour session differently |
The Deal That Shows the Priority
Lilly announced the AtaiBeckley acquisition on July 16, 2026. The structure was 6.75 dollars per share in cash plus contingent value rights. That is roughly 2.8 billion upfront and up to 3.8 billion in total.
The lead compound is BPL-003, a synthetic intranasal form of 5-MeO-DMT. It carries FDA Breakthrough Therapy Designation and has entered Phase 3. We covered the transaction when it was announced.
Read the Lilly release and the framing is hard to miss. Durable results, following a visit of about two hours. The clinic visit length is presented as a feature of the product.
The Field Now Spans 15 Minutes to 12 Hours
Session length has become the axis that separates these programs. The figures below come from company disclosures and trial reports, not head to head comparisons, so treat them as directional.
| Compound | Developer | Reported time in clinic |
|---|---|---|
| GH001, inhaled mebufotenin | GH Research | Psychoactive peak of roughly 9 to 14 minutes per dose |
| Spravato, intranasal esketamine | Johnson & Johnson | Two hour minimum monitoring. Approved and reimbursed today |
| BPL-003, intranasal mebufotenin | Eli Lilly | About two hours on average in Phase 2b |
| HLP004, 5-HT2A agonist | Helus Pharma | Discharge within three hours in Phase 1 |
| CYB003, deuterated psilocin | Cybin | Four to six hours |
| DT120, oral LSD | Definium | About six hours, with no psychotherapy component required |
| MM120, oral LSD | MindMed | Eight to twelve hours |
The spread is nearly fiftyfold. No other variable in this field separates candidates that dramatically. Efficacy claims across these programs are far more tightly clustered than session length is.
Spravato Already Proved the Two Hour Model
The two hour session is not a projection. It is the operating reality for thousands of clinics right now.
The Spravato REMS requires a healthcare provider onsite and a minimum of two hours of monitoring after every dose. That includes blood pressure before dosing and again at roughly 40 minutes, plus respiratory status and pulse oximetry. Discharge depends on clinical assessment, so sessions can run longer.
That matters more than any pipeline chart. A two hour supervised psychiatric administration already has a billing pathway, a monitoring protocol and payer acceptance. The infrastructure question has been answered once.
What a CEO Said, and What He Actually Showed
Michael Halstead became chief executive of Helus Pharma in August 2026. He previously served as president of Intra-Cellular Therapies before Johnson & Johnson acquired it for 14.6 billion dollars.
Speaking to PharmaVoice on August 18, he described a building-block approach to growth. “You can’t suddenly drop a battleship on top of the organization,” he said. He suggested Helus could file a new drug application as early as 2028.
The number worth extracting is different. Helus reports that HLP004 supported discharge within three hours in Phase 1. The company is describing its anxiety candidate partly in terms of how long the patient occupies a room.
Be Careful With the Efficacy Figures
The same interview carries a striking result for HLP003, the company’s depression candidate. Seven participants who completed twelve month follow up all met response criteria. Five of the seven, or 71 percent, were in remission.
Seven people is not a trial result. It is a completer subgroup at one timepoint. Percentages calculated on seven patients move by 14 points every time one person changes category.
The 2028 filing target is also a company projection. It comes from a chief executive with an obvious interest in how the pipeline is received. Neither figure should anchor a business decision.
Why Session Length Is an Operations Number
Session length sets almost everything downstream. It determines how many patients one room serves in a day. It determines how many staff hours each patient consumes.
Consider the arithmetic. A room running two hour sessions can serve three or four patients in a clinical day. The same room running eight hour sessions serves one.
That is not a small efficiency difference. It is a different business. Revenue per room, staffing ratios and the number of rooms a practice needs all change with it.
The Buildout Risk Is Real
Clinics planning for psychedelic services face a timing problem. Rooms, leases and staffing models get decided years before any approval lands.
Suppose approved products arrive at two to three hours. A practice built for full day sessions then carries oversized rooms and undersized throughput. If the reverse happens, the practice is short on space.
The current evidence leans toward shorter. The compound with the most money behind it runs about two hours. The one with an approved precedent runs two hours. We walked through the related infrastructure question in our look at intravenous psychedelic trials.
Longer Sessions Are Not Automatically Losing
There is a counterargument worth taking seriously. Longer sessions may produce better outcomes for some conditions, and payers reimburse outcomes rather than convenience.
Definium’s oral LSD candidate is instructive here. Its sessions run about six hours, but the trials required no psychotherapy component. We covered that design in our piece on its second Phase 3 result.
Long chair time with light staffing is one cost structure. Long chair time with a therapist in the room is another. Duration and labor intensity are separate variables, and conflating them produces bad forecasts. The ongoing argument over what the therapy component even is sits directly on top of this.
What Would Settle It
Two things would resolve the question, and neither has happened yet.
The first is a reimbursement decision. Suppose payers set materially different rates for a two hour session and an eight hour one. That pricing would shape the field faster than any trial result.
The second is a dose response answer. The VA is running a phase 3 comparing a higher and lower dose of psilocybin in veterans. It began enrolling this month. Dose is the closest available proxy for duration.
The Practical Read
Nothing here requires an immediate decision. Approvals remain years away, and the 2028 dates being floated are company targets.
What it does justify is a design assumption. Any practice modeling psychedelic services should run the numbers at two to three hours per session first. Then test whether a longer model still holds up.
The largest buyer in the industry made that assumption with 3.8 billion dollars. That is worth more than a pipeline projection.
This article is for informational purposes and is not medical advice or investment advice. The compounds described remain investigational except where noted. Session durations reflect company disclosures and may change as trials progress.
